Skip to main content
U.S. flag

An official website of the United States government

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Table of Contents

Last Updated: February 23, 2021

Below is an overview of the sections found in the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.

What’s New in the Guidelines

The COVID-19 Treatment Guidelines Panel’s Statement on the Emergency Use Authorization of the Bamlanivimab Plus Etesevimab Combination for the Treatment of COVID-19

The COVID-19 Treatment Guidelines Panel’s Statement on the Use of Tocilizumab (and Other Interleukin-6 Inhibitors) for the Treatment of COVID-19

Introduction

Overview of COVID-19

  • Testing for SARS-CoV-2 Infection
  • Prevention and Prophylaxis of SARS-CoV-2 Infection
  • Clinical Spectrum of SARS-CoV-2 Infection

Care of Critically Ill Patients With COVID-19

  • General Considerations
  • Infection Control
  • Hemodynamics
  • Oxygenation and Ventilation
  • Acute Kidney Injury and Renal Replacement Therapy
  • Pharmacologic Interventions
  • Extracorporeal Membrane Oxygenation

Therapeutic Management of Patients With COVID-19

Antiviral Drugs That Are Approved or Under Evaluation for the Treatment of COVID-19

  • Remdesivir
    • Table 2a. Remdesivir: Selected Clinical Data
  • Chloroquine or Hydroxychloroquine With or Without Azithromycin
    • Table 2b. Chloroquine or Hydroxychloroquine With or Without Azithromycin: Selected Clinical Data
  • Ivermectin
    • Table 2c. Ivermectin: Selected Clinical Data
  • Lopinavir/Ritonavir and Other HIV Protease Inhibitors
  • Table 2d. Characteristics of Antiviral Agents That Are Approved or Under Evaluation for Treatment of COVID-19

Anti-SARS-CoV-2 Antibody Products

  • Convalescent Plasma
  • Immunoglobulins: SARS-CoV-2 Specific
  • Anti-SARS-CoV-2 Monoclonal Antibodies
    • Table 3a. Anti-SARS-CoV-2 Monoclonal Antibodies: Selected Clinical Data
  • Table 3b. Characteristics of SARS-CoV-2 Antibody-Based Products Under Evaluation for the Treatment of COVID-19

Cell-Based Therapy Under Evaluation for the Treatment of COVID-19

Immunomodulators Under Evaluation for the Treatment of COVID-19

  • Corticosteroids
    • Table 4a. Corticosteroids: Selected Clinical Data
  • Interferons (Alfa, Beta)
  • Interleukin-1 Inhibitors
  • Interleukin-6 Inhibitors
  • Kinase Inhibitors: Baricitinib and Other Janus Kinase Inhibitors, and Bruton’s Tyrosine Kinase Inhibitors
  • Immunoglobulins: Non-SARS-CoV-2 Specific
  • Table 4b. Characteristics of Immunomodulators Under Evaluation for the Treatment of COVID-19

Antithrombotic Therapy in Patients With COVID-19

Supplements

  • Vitamin C
  • Vitamin D
  • Zinc Supplementation and COVID-19

Considerations for Certain Concomitant Medications in Patients With COVID-19

COVID-19 and Special Populations

  • Special Considerations in Pregnancy
  • Special Considerations in Children
  • Special Considerations in Adults and Children With Cancer
  • Special Considerations in Solid Organ Transplant, Hematopoietic Stem Cell Transplant, and Cellular Therapy Candidates, Donors, and Recipients
  • Special Considerations in People With Human Immunodeficiency Virus
  • Influenza and COVID-19

Appendix A, Table 1. COVID-19 Treatment Guidelines Panel Members

Appendix A, Table 2. COVID-19 Treatment Guidelines Panel Financial Disclosure for Companies Related to COVID-19 Treatment or Diagnostics